SecBot SecBot
PRESS-RELEASE ·Filed Jun 13, 2026

ASND

Ascendis Pharma
BULLISH
Impact 7/10
Horizonweeks Processed5mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

The sustained efficacy and safety data through 3.5 years de-risks YORVIPATH's long-term profile and supports continued prescription growth. Monitor upcoming quarterly earnings for revenue ramp and any competitive developments.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$223.29
T+0 close · Jun 13, 2026 · via day close
Latest settled
+16.80%
T+60 · $260.81
Vs SPY
+15.80%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 15 $223.29entry
  2. T+1 · 5mo ago +3.54%α +4.14% · $231.20
  3. T+5 · 5mo ago +2.11%α +3.49% · $228.00
  4. T+20 · 4mo ago +18.78%α +19.53% · $265.22
  5. T+60 · 2mo ago +16.80%α +15.80% · $260.81
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Ascendis Pharma announced sustained efficacy and safety data from the Phase 3 PaTHway Trial of TransCon PTH (YORVIPATH) in hypoparathyroidism through 3.5 years (Week 182). 86% of patients met the multi-component endpoint, 89% completed the trial, and key renal, bone, and quality-of-life benefits were maintained with no new safety signals. This positive long-term data reinforces the drug's profile and supports continued commercial adoption, though the stock has historically underperformed following prior positive reports.

Key Facts

  • 86% of patients were responders for the multi-component endpoint (normocalcemia, no active vitamin D, ≤600 mg/day calcium) at Week 182.
  • 89% of patients completed the 3.5-year trial.
  • 100% of patients achieved independence from active vitamin D; 96% from therapeutic calcium doses.
  • Mean eGFR increased by 11.0 mL/min/1.73 m² from baseline and was maintained through Week 182, contrasting with expected age-related decline.
  • Mean 24-hour urine calcium normalized within 26 weeks and remained normal through Week 182.
  • No new safety signals; no discontinuations related to study drug; no anti-PTH antibodies developed.
  • TransCon PTH is already approved as YORVIPATH in the US, EU, and other jurisdictions.
  • Trial enrolled 82 adults (85% post-surgical, 15% non-surgical hypoparathyroidism).

Financial Impact

Positive long-term data supports YORVIPATH's commercial potential in hypoparathyroidism, a chronic disease with no other PTH-replacement therapy. No revenue or financial figures were disclosed in the press release.

revenuemarket share

Risk Factors

  • Competition from other hypoparathyroidism therapies in development.
  • Pricing and reimbursement challenges in key markets.
  • Potential for regulatory setbacks in additional jurisdictions.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
96% bullish (26 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3311416

Track record

41 reports on ASND

Performance horizon

13 of 18 bullish or bearish reports moved the stock their way by T+60. Best: +26.62% at T+20 after the Jun 2, 2026 report. 24 of 26 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $271.96 Now $275.39 +1.26% settles Feb 12
  2. Nov 12, 20264d ago 6-K Neutral 2/10 Entry $275.39 Now $275.39 +0.00% settles Feb 11
  3. Nov 12, 20264d ago 6-K Bullish 6/10 Entry $267.07 Now $275.39 +3.12% settles Feb 10
  4. Nov 12, 20264d ago Press Release Neutral 5/10 Entry $267.07 Now $275.39 +3.12% settles Feb 10
  5. Nov 6, 202610d ago 6-K Bullish 6/10 Entry $259.85 Now $275.39 +5.98% settles Feb 5
  6. Nov 6, 202610d ago Press Release Bullish 6/10 Entry $256.82 Now $275.39 +7.23% settles Feb 4
  7. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $253.45 Now $275.39 +8.66% settles Feb 3
  8. Nov 2, 202614d ago Institutional Cluster Bullish 4/10 Entry $250.17 Now $275.39 +10.08% settles Feb 1
  9. Oct 26, 202621d ago 6-K Bullish 5/10 Entry $245.85 Now $275.39 +12.02% settles Jan 25
  10. Oct 16, 20264w ago 6-K Bullish 7/10 Entry $225.25 Now $275.39 +22.26% settles Jan 13
Showing 10 of 41

US Market Status

Market Closed · Opens Wed (12h 7m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 13, 2026